Sign In
Buy NERV
$4.68
-0.0700 (-1.47%)
At Close: Jun 03, 2026
Minerva Shares Tank 72% As Schizophrenia Drug Misses Trial Goals
11:50am, Sunday, 31'st May 2020
Shares in Minerva Neurosciences Inc. (NERV) tanked 72% after the company's experimental drug roluperidone tailored for the treatment of schizophrenia did not meet its primary and key secondary endpoin
Here's Why Minerva Neurosciences Collapsed Today
08:50pm, Friday, 29'th May 2020
The company's lead drug candidate flopped in a phase 3 trial. Can a longer-term follow-up study resurrect the asset?
Mid-Afternoon Market Update: U.S. Stocks Turn Positive; Crude Oil Surges Over 5%
07:10pm, Friday, 29'th May 2020Mid-Day Market Update: Canopy Growth Slides After Q4 Results; Sonoma Pharmaceuticals Shares Surge
04:00pm, Friday, 29'th May 2020Minerva Schizophrenia-Drug Trial Misses Key Endpoints
03:48pm, Friday, 29'th May 2020
Roluperidone, a Minerva Neurosciences schizophrenia-drug candidate, failed to meet its key endpoints. But the company is undaunted.
Zacks.com featured highlights include: Minerva Neurosciences, Liquidia Technologies, Calix, Avenue Therapeutics and ExOne
02:31pm, Friday, 29'th May 2020
Zacks.com featured highlights include: Minerva Neurosciences, Liquidia Technologies, Calix, Avenue Therapeutics and ExOne
The 64 mg and 32 mg doses were not statistically significantly different from placebo at Week 12 on the primary endpoint, the PANSS Marder Negative Symptoms...
Minerva Neurosciences' stock plummets after schizophrenia treatment disappoints in phase 3 study
02:15pm, Friday, 29'th May 2020
Shares of Minerva Neurosciences Inc. plummeted 67% toward a 7-month low in morning trading Friday, enough to pace all Nasdaq losers, after the biopharmaceutical company announced disappointing result
Minerva Neurosciences, Inc. (NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, announced today that the Phase 3 trial
Minerva Shares Halted On Third Circuit Breaker Of The Day, Stock Down 81.2% For Session
12:00am, Friday, 29'th May 2020Minerva Neurosciences Option Alert: Jul 17 $22.5 Calls at the Ask: 2939 @ $4.0 vs 40 OI; Ref=$13.585
12:00am, Thursday, 28'th May 2020Small Drug Industry Prospects Bright Amid Coronavirus Gloom
01:40pm, Wednesday, 27'th May 2020
Small Drug Industry Prospects Bright Amid Coronavirus Gloom
The Daily Biotech Pulse: Cumberland's Positive Anti-Bacterial Readout, FDA Nods For Bristol-Myers, Astellas
11:25am, Wednesday, 27'th May 2020Les marques dans le monde d'après
06:00am, Wednesday, 27'th May 2020
A propos du monde d'après pour les marques, les scenarii les plus contradictoires sont évoqués par les instituts d'études, les publicitaires ou...
